Certara Inc. Faces Analyst Split & Barclays Downgrade Amid Drug‑Discovery Tech Potential
Certara Inc. faces analyst split and a Barclays downgrade, but its biosimulation platform could boost drug‑development speed—watch for revenue wins and partnerships.
3 minutes to read